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.-X. Li).Abstract The purpose of this study was to investigate the hydrolyzation of aspirin during the
process of dissolution testing for aspirin delayed-release tablets. Hydrolysis product of salicylic acid
can result in adverse effects and affect the determination of dissolution rate assaying. In this study,
the technique of differential spectra was employed, which made it possible to monitor the
dissolution testing in situ. The results showed that the hydrolyzation of aspirin made the percentage
of salicylic acid exceed the limit of free salicylic acid (4.0), and the hydrolyzation may affect the
quality detection of aspirin delayed-release tablets.
& 2012 Xian Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Aspirin is widely used as an anti-rheumatic, antipyretic and
anti-thrombosis drug [1,2]. The main adverse effects producedrsity. Production and hosting
n Jiaotong University.
.002
8215 (mobile).
hoo.com.cn (Y. Wang),by aspirin are gastrointestinal [3], tinnitus [4], Reye’s syn-
drome [5] and so on. These adverse effects of aspirin result
almost all from the salicylic acid.
The hydrolyzation of aspirin belongs to second order
reaction [6], but with the pH value kept constant, the
hydrolyzation was presumed to be pseudo-ﬁrst order reaction.
In recent years, some articles have reported this reaction, but
there is no article reporting the effect of hydrolyzation on
dissolution testing.
Salicylic acid produced by aspirin in the process of manufactur-
ing or hydrolysis will affect the dissolution testing and assaying.
Therefore, it is important to check out the limit of free salicylic
acid in aspirin delayed-release tablets and other preparations. In
USP30-NF-25, the limit of free salicylic acid in aspirin delayed-
release tablets is not more than 4.0% of the labeled amount.
In this study we researched the hydrolyzation of aspirin
during the process of dissolution test for aspirin delayed-
release tablets.
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2.1. Instrument
A ﬁber-optic drug dissolution in-situ test system (FODT)
was developed by Professor JIan Chen’s group of Xinjiang265nm 
Figure 1 UV absorbance spectra of salicylic acids and aspirin.
Table 1 Calibration curve equations of aspirin in six
channels.
Channel Calibration curve
equations
Correlation
coefﬁcient (r)
Channel 1 C¼0.2þ295.9A 0.9998
Channel 2 C¼1.2þ305.8A 0.9996
Channel 3 C¼1.0þ305.8A 0.9999
Channel 4 C¼1.4þ305.8A 0.9999
Channel 5 C¼0.5þ294.1A 0.9997
Channel 6 C¼0.6þ287.4A 0.9998
UV C¼1.5þ305.4A 0.9999
Figure 2 Release proﬁles of aspirin delayed-release tablets.
Table 2 Comparison of the accumulative dissolution rate (%) fo
Channel 1 2 3 4
FODT 95.8 91.7 95.8 94.4
UV 95.0 91.0 94.0 94.0
SD 0.8 0.7 1.8 0.4Medical University and Xinjiang FOCS Bio-Tech Develop-
ment Co., Ltd. A UV–visible spectrophotometer (Cintra 40,
GBC Scientiﬁc Equipment Pty. Ltd., Australia) was utilized
for the off-line control of UV determination.2.2. Reagents and drugs
Aspirin (Lot no. 100113-200302) and salicylic acid (Lot no.
100405-100560) reference substances were obtained from
the National Institute for the Control of Pharmaceutical
and Biological Products of China; aspirin enteric-coated
tablets (0.1 g) were supplied by Bayer Vital GmbH (Lot no.
BTA6WK5); and all other reagents were of A.R. grade;
puriﬁed water was prepared in the laboratory and degassed
before use.2.3. Preparation of pH 6.8 phosphate buffer
A mixture of 0.1 M hydrochloric acid and 0.2 M tribasic
sodium phosphate (3:1) was prepared; if necessary, it was
adjusted with 2 M hydrochloric acid or 2 M sodium hydroxide
to pH of 6.870.05.2.4. Preparation of calibration solutions
Calibration solutions of aspirin and salicylic acid were
prepared with pH 6.8 phosphate buffer. The aspirin calibra-
tion solutions were prepared at concentrations from 20.0 to
120.0 mg/mL. The molarity of salicylic acid solution equaled
that of the labeled amount of 100 mg of aspirin delayed-
release tablets diluted in 1000 mL dissolution media, the
salicylic acid calibration solutions were prepared at concen-
trations from 15.4 to 92.4 mg/mL.2.5. UV spectral characteristics of aspirin
Acetylsalicylic acid is stable in dry air, but gradually hydrolyzes
in contact with moisture containing acetic and salicylic acids.
Solutions of aspirin and salicylic acid reference substance were
prepared with phosphate buffer (pH 6.8) and scanned by UV.2.6. Linearity
A series of different concentrations of aspirin substance at
20.0%, 40.0%, 60.0%, 80.0%, 100.0% and 120.0% were
prepared. The linearity of each set of standard solutions was
performed to test each individual probe.r aspirin delayed-release tablets by FODT and UV.
5 6 Average RSD (%)
90.9 92.5 93.5 2.1
91.2 93.5 93.1 1.6
0.3 1.0 0.4 0.9
Y. Wang et al.3882.7. Release test
Release testing was performed with Ch.P Apparatus I, in
750 mL of pH 1.2 dissolution medium for ﬁrst 2 h, and
250 mL of pH 6.8 phosphate buffer was added for the next
45 min, using probes with 5 mm path lengths. The stirring
speed was 100 rpm. The detection and reference wavelengths
were set at 280 nm in the acid stage and about 265 nm in the
buffer stage, respectively. The real-time drug release data and
proﬁles were obtained by FODT.
For the UV control analysis, dissolution samples were
withdrawn at the end of the dissolution test and ﬁltered using
0.80 mm ﬁlter membrane. Then we determined the amount of
aspirin dissolved by UV at a large wavelength of aspirin and
salicylic acid.3. Results and discussion
3.1. UV spectral characteristics of aspirin
The absorption spectra of aspirin and salicylic acid in
phosphate buffer (pH 6.8) are shown in Fig. 1. The absorption
peaks were at 233 nm and 296 nm. At the wavelength of
265 nm, aspirin and salicylic acid had a different absorbance,
so it affected the determination of dissolution rate. According
to the UV analysis method in USP, the aspirin enteric-coated
tablets were determined at 265 nm, and at the same time
the absorbance of salicylic acid was observed at 265 nm as the
same absorption point as that of aspirin to deduct the
interference by salicylic acid.Figure 3 UV absorbance spectra of aspirin at different time
points.
Table 3 Percentage of salicylic acid in the dissolution test for as
Channel 1 2 3
Absorbance 0.069 0.072 0.0
Percentage of salicylic acid 3.8 3.9 4.33.2. Linearity
The series of standard solutions can obtain a proper
absorbance range by using a probe of 5 mm path length.
The calibration curve equations of aspirin are shown in
Table 1.3.3. Release test
Due to the use of two dissolution media (one is the pH 1.2
medium and the other is the pH 6.8 medium), FODT had
to recalibrate for the second medium [7]. Fortunately the
software was compiled for delayed-release dosage form with
the technique of differential spectra, and we were able to
acquire a complete proﬁle for the entire release process. So the
difﬁculty was solved by scanning the blank twice. The
dissolution proﬁles by the FODT are shown in Fig. 2.
Table 2 shows the cumulative percentages of drug dissolved
from the tablets determined by FODT and UV. There was no
signiﬁcant difference between the methods of FODT and UV
(P40.05).
Drug dissolution–release proﬁles were obtained in-situ
by FODT; the data acquisition interval for FODT was
preset at 15 min. The absorption spectra of aspirin displayed
differences. At 296 nm, absorptive changes are shown
in Fig. 3. It shows that the amount of salicylic acid increased
when aspirin was dissolved out constantly from the
tablets.
At the end of testing, we detected the absorbance of
dissolution samples at 296 nm by UV and calculated the
percentage of salicylic acid. The results are listed in Table 3.
The hydrolyzation of aspirin made the percentage of salicylic
acid exceed the limit of free salicylic acid (4.0). We can
conclude that the hydrolyzation may affect the detection
quality of aspirin delayed-release tablets.
Determination of the release rate of active ingredients
from drug formulations is an important procedure in phar-
maceutical laboratories. Traditionally, it is analyzed by UV
and HPLC. When detecting the dissolution rate of drugs
which are capable of hydrolysis with traditional methods, one
should quickly remove, ﬁlter and dilute samples, and then
immediately detect the accumulative dissolution rate (%).
Otherwise, it will affect the results of dissolution. It is time
consuming and can give only little information on the
dissolution behavior of drugs. FODT was proven to be useful
for pharmaceutical solid formulation, productive, time saving
and can acquire more information than conventional methods.
It not only gives the dissolution proﬁles of drugs, but also
gives information on absorption spectra at any time during
dissolution tests, enabling us to ﬁnd all changes during
the tests.pirin delayed-release tablets.
4 5 6 Mean
78 0.070 0.080 0.080 0.075
3.8 4.4 4.4 4.1
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